Jim Cramer provides his opinion on caller-favorite stocks, but says this one's got a big problem with trust. » Read More
RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.
Jim Cramer rattles off his take on caller favorite stocks, including this medical tech play.
U.S. stocks closed higher Thursday, as oil gains and Facebook outweighed pressure from declines in biotech stocks and concerns about economic growth.
After rash of earnings reports, Abbott Labs, Bristol-Myers Squibb, Celgene and Eli Lilly shares suffer. CNBC's Meg Tirrell reports.
A group of widely owned stocks may be at risk of taking a hit as investors unwind their exposure to equities amid increased volatility in 2016.
JMP Securities President Mark Lehmann explains why now is the time to get in on biotech stocks.
Celgene Chairman and CEO Bob Hugin, discusses his outlook for the health care industry, and M&A in the space.
Celgene announced Mark Alles will be named CEO to replace Bob Hugin.
Celgene's Mark Hugin is replaced by Mark Alles as CEO, and the company lowers earnings estimates, reports CNBC's Sue Herera.
The JPMorgan Health Care Conference, which kicks off next week, could take on a more muted tone than in previous years.
Jim Cramer prepares investors with his shopping list of stocks to avoid and buy amid the worldwide sell-off.
RBC Capital Markets analyst Michael Yee says there are three biotech stocks to own next year no matter how the sector performs in 2016.
Uri Gruenbaum, CEO of TipRanks, listed the top 10 biotech analysts on Wall Street based on the returns they've generated since 2009.
“Mad Money” host Jim Cramer is telling investors which stock is headed higher for the long-term.
Jim Cramer prepares investors for the biotech group to come roaring back in 2016, and shares his top picks.
Wednesday stocks on the move
*Nike reverses course after hitting record high. *Celgene up after settling patent litigation. Dec 23- Wall Street rallied for the third straight session on Wednesday, led by sharp gains in energy stocks as a rebound in oil prices boosted sentiment heading into the Christmas holiday.
*Nike reverses course after hitting record high. *Celgene up after settling patent litigation. The market rallies into Christmas, "said Jeff Clark, trading analyst at Stansberry Research in Baltimore.
*Nike hits record high after quarterly results. *Celgene up after settling patent litigation. The market rallies into Christmas, "said Jeff Clark, trading analyst at Stansberry Research.
Some of the names on the move ahead of the open.